Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

CSPC's Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company's First Recombinant Protein Vaccine Candidate to Enter Clinical Trials
CompanyDrug

CSPC’s Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company’s First Recombinant Protein Vaccine Candidate to Enter Clinical Trials

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Class 1 innovative drug, a recombinant herpes zoster vaccine (SYS6052), has received IND approval from the U.S. FDA to initiate clinical…

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

GenFleet's Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

GenFleet’s Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study

CompanyDeals

InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy

CompanyDrug

OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma

CompanyDeals

ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs

CompanyDrug

Shanghai Henlius’ PD-1 Inhibitor Serplulimab Gains Australian Clearance for Phase III Study

CompanyDrug

Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer

CompanyDrug

Abbisko’s ABSK021 Gets CDE Approval for Phase III Study in Giant Cell Tumor of Tendon Sheath

CompanyDrug

Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer

Show More